Conditions: Moderate to Severe Plaque-type Psoriasis
Keywords: skin condition skin disease itching condition psoriasis vulgaris relapsing psoriasis remitting psoriasis immune-mediated systemic disease skin lesions, red skin lesions scaly patches papules, plaques itching auto-immune plaque-type psoriasis plaque
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 772
Healthy volunteers: no

Brief summary:
This study is designed to support the optimal use of secukinumab by providing data to refine guidance on dosing flexibility in patients with psoriasis. The purpose of the study is to explore the effects of dosage interval shorteng to achieve PASI 90 at week 32 for patients who had less than almost clear skin at week 16.

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: Secukinumab
Intervention descriptions: intervention 1: None

Protocol document: